Abbott Laboratories (ABT) received positive analyst sentiment, including a price target increase to $169 from Barclays, following the showcase of its new AI-powered diabetes management feature, Libre Assist, at CES.
- The company reported Q3 2025 revenue of $11.37 billion (+6.9% YoY) and extended its 54-year dividend growth streak by approving a quarterly dividend of $0.63 per share.
- Evercore ISI also lifted its price target to $144, with both firms citing strong organic revenue growth and device segment performance as key drivers.
- ABT closed January 5 up 1.82% at $126.45 and is scheduled to report critical Q4 2025 earnings on January 22, 2026.